Massachusetts Ended GLP-1 Coverage for State Employees
State insurance programs cut coverage for weight loss medications, affecting over 22,000 members across the commonwealth.
Updated on Oct. 1, 2026 in Weight Loss
Live Poll
Should states prioritize saving money by cutting insurance coverage for weight loss medications?
Massachusetts eliminated coverage for GLP-1 weight loss drugs within the fiscal 2027 budget and through a Group Insurance Commission board vote. The decision impacts the 22,000 members who previously relied on these plans for weight loss treatment.
Why it matters
The coverage removal was a direct response to rising pharmaceutical costs and a directive from the Healey administration to trim agency spending by $120 million. This change highlights the ongoing fiscal pressure state health programs face when managing expensive, high-demand obesity medications.
Official fiscal 2027 budget documents confirm that the state removed coverage for GLP-1 drugs that had previously cost $46 million annually. While projections suggest spending could drop if plans leverage federal price negotiations, the long-term impact on weight loss outcomes remains unknown.
The players
Healey administration
The current state executive branch that directed agencies to cut spending to address budget pressures.
Group Insurance Commission
The state agency that provides health insurance to over 460,000 public employees and retirees.
Novo Nordisk
A pharmaceutical company specializing in diabetes and obesity treatments, including Wegovy and Ozempic.
Kiame Mahaniah
The Health and Human Services Secretary who has indicated that coverage could potentially be restored in the future.
The details
The Group Insurance Commission (GIC) manages benefits for 460,000 public employees and retirees, and the decision to remove coverage followed a divided board vote in February 2026. This move was part of a broader strategy to offset budget pressures after the GIC received a $300 million emergency funding infusion. These medications function by mimicking glucagon-like peptide-1, which regulates appetite and glucose metabolism, but their high list prices have become a central point of contention for state insurers.
Timeline
February 2026: The Group Insurance Commission board voted to end GLP-1 coverage.
Fiscal 2027: The state budget officially removed coverage for these medications.
January 1, 2027: Novo Nordisk list prices for Wegovy and Ozempic decrease to $675.
Health Landscape
This policy change reflects a broader national trend of insurers grappling with the high costs associated with GLP-1 therapies. It represents a significant departure from previous coverage models as states attempt to balance medical innovation with strict fiscal sustainability.
If you are a member of the GIC or MassHealth, review your current benefit plan documents to confirm your personal coverage status for weight loss medications. Discuss alternative treatment options or coverage questions with your primary care physician to understand how this change affects your care plan.
The takeaway
The exclusion of weight loss drugs from state insurance plans is primarily a budget-driven decision rather than a clinical one. Patients affected by this change should consult their physician to discuss alternative options and monitor updates regarding future coverage policies.
Further reading
Learn more about the current state of Weight Loss treatments and the evolving standards for care.
Live Poll
Should states prioritize saving money by cutting insurance coverage for weight loss medications?
